{"schema_version":"secwatch.filing_event.v1","accession":"0000926617-25-000004","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.645109+00:00","generated_at":"2026-05-16T20:04:50.624783+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aspira Women's Health Q3 revenue flat at $2.3M; gross margin expands to 64.1%","bullets":["Nine-month gross profit $4.5M (+12.2% YoY); margin 64.1% vs 58.4%.","Operating expenses down 34% to $11.1M; cash burn reduced 54.5% to $5.0M.","Average unit price per test +7% YoY; sales per FTE up 167% in Q3.","Shift to profitable revenue; OvaSuite adopted by large IDN for O-RADS 4 patients.","Progress on ENDOinform endometriosis diagnostic; milestones toward commercial readiness."],"urls":{"canonical":"https://secwatch.observer/filing/0000926617-25-000004","json":"https://secwatch.observer/filing/0000926617-25-000004.json","markdown":"https://secwatch.observer/filing/0000926617-25-000004.md","text":"https://secwatch.observer/filing/0000926617-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000092661725000004/0000926617-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000092661725000004/awhl-20251114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:04:50.624783+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}